Cytokinetics Announces Six Upcoming Presentations at the American Heart Association Scientific Sessions 2024
Cytokinetics (CYTK) announced six presentations scheduled for the American Heart Association Scientific Sessions 2024 in Chicago from November 16-18, 2024. The presentations focus on two key drugs: Aficamten and Omecamtiv Mecarbil.
Three presentations will discuss Aficamten's results from the SEQUOIA-HCM and FOREST-HCM trials, including oxygen uptake recovery patterns, efficacy in patients eligible for septal reduction therapy, and quality of life improvements. Two presentations will cover Omecamtiv Mecarbil's findings from the GALACTIC-HF trial, examining its effects on ventricular arrhythmias and efficacy across age groups. An additional presentation will address healthcare costs in obstructive hypertrophic cardiomyopathy patients.
Cytokinetics (CYTK) ha annunciato sei presentazioni programmate per le American Heart Association Scientific Sessions 2024 a Chicago dal 16 al 18 novembre 2024. Le presentazioni si concentrano su due farmaci chiave: Aficamten e Omecamtiv Mecarbil.
Tre presentazioni discuteranno i risultati di Aficamten dagli studi SEQUOIA-HCM e FOREST-HCM, inclusi i modelli di recupero dell'assunzione di ossigeno, l'efficacia nei pazienti idonei per la terapia di riduzione settale e i miglioramenti nella qualità della vita. Due presentazioni tratteranno i risultati di Omecamtiv Mecarbil dallo studio GALACTIC-HF, esaminando i suoi effetti sulle aritmie ventricolari e l'efficacia tra i gruppi di età. Un'ulteriore presentazione affronterà i costi sanitari nei pazienti con miocardiopatia ipertrofica ostruttiva.
Cytokinetics (CYTK) anunció seis presentaciones programadas para las American Heart Association Scientific Sessions 2024 en Chicago del 16 al 18 de noviembre de 2024. Las presentaciones se centran en dos medicamentos clave: Aficamten y Omecamtiv Mecarbil.
Tres presentaciones discutirán los resultados de Aficamten de los ensayos SEQUOIA-HCM y FOREST-HCM, incluidos los patrones de recuperación de la captación de oxígeno, la eficacia en pacientes elegibles para terapia de reducción septal y las mejoras en la calidad de vida. Dos presentaciones cubrirán los hallazgos de Omecamtiv Mecarbil del ensayo GALACTIC-HF, examinando sus efectos sobre las arritmias ventriculares y la eficacia entre grupos de edad. Una presentación adicional abordará los costos de atención médica en pacientes con miocardiopatía hipertrófica obstructiva.
사이토키네틱스(CYTK)는 2024년 11월 16일부터 18일까지 시카고에서 열리는 미국심장협회 과학 세션 2024에서 예정된 6개의 발표를 발표했습니다. 발표는 Aficamten과 Omecamtiv Mecarbil라는 두 가지 주요 약물에 중점을 둡니다.
세 개의 발표에서는 SEQUOIA-HCM 및 FOREST-HCM 시험에서의 Aficamten의 결과, 산소 섭취 회복 패턴, 심실 축소 요법에 적합한 환자에서의 효능, 삶의 질 향상에 대해 논의합니다. 두 개의 발표에서는 GALACTIC-HF 시험에서의 Omecamtiv Mecarbil의 발견을 다루며 심실 부정맥에 대한 효과와 연령 그룹 간 효능을 조사합니다. 추가 발표는 폐쇄성 비대 심근병 환자의 건강 관리 비용을 다룰 것입니다.
Cytokinetics (CYTK) a annoncé six présentations prévues lors des American Heart Association Scientific Sessions 2024 à Chicago du 16 au 18 novembre 2024. Les présentations se concentrent sur deux médicaments clés : Aficamten et Omecamtiv Mecarbil.
Trois présentations aborderont les résultats d'Aficamten issus des essais SEQUOIA-HCM et FOREST-HCM, y compris les modèles de récupération de la consommation d'oxygène, l'efficacité chez les patients éligibles pour une thérapie de réduction septale et les améliorations de la qualité de vie. Deux présentations couvriront les résultats d'Omecamtiv Mecarbil issus de l'essai GALACTIC-HF, examinant ses effets sur les arythmies ventriculaires et son efficacité selon les tranches d'âge. Une présentation supplémentaire traitera des coûts de santé chez les patients atteints de cardiomyopathie hypertrophique obstructive.
Cytokinetics (CYTK) hat sechs Präsentationen angekündigt, die für die American Heart Association Scientific Sessions 2024 vom 16. bis 18. November 2024 in Chicago geplant sind. Die Präsentationen konzentrieren sich auf zwei wichtige Arzneimittel: Aficamten und Omecamtiv Mecarbil.
Drei Präsentationen werden die Ergebnisse von Aficamten aus den SEQUOIA-HCM- und FOREST-HCM-Studien erörtern, einschließlich der Wiederherstellungsmuster der Sauerstoffaufnahme, der Wirksamkeit bei Patienten, die für die septale Reduktionstherapie in Frage kommen, und der Verbesserung der Lebensqualität. Zwei Präsentationen werden die Ergebnisse von Omecamtiv Mecarbil aus der GALACTIC-HF-Studie abdecken und die Auswirkungen auf ventrikuläre Arrhythmien sowie die Wirksamkeit in verschiedenen Altersgruppen untersuchen. Eine zusätzliche Präsentation wird die Gesundheitskosten bei Patienten mit obstruktiver hypertropher Kardiomyopathie ansprechen.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced six upcoming presentations at the American Heart Association Scientific Sessions 2024 taking place in Chicago, IL from November 16, 2024 - November 18, 2024.
Aficamten
Title: Modifiability of Post-Exercise Oxygen Uptake Recovery Patterns: A Substudy of the SEQUOIA-HCM Trial
Presenter: Gregory D. Lewis, M.D., Jeffrey and Mary Ellen Jay Chair and Section Head, Heart Failure Medical Director, Cardiopulmonary Exercise Testing Laboratory, Professor of Medicine, Harvard Medical School
Date: November 17, 2024
Session Title: Advances in Identification and Management of Hypertrophic Cardiomyopathy
Session Time: 9:30 AM – 10:55 AM CT
Presentation Time: 10:00 AM – 10:05 AM CT
Location: Zone 2‚ Moderated Digital Poster 9
Title: Efficacy and Safety of Aficamten in Patients Guideline-Eligible for Septal Reduction Therapy in the FOREST-HCM Trial
Presenter: Ahmad Masri, M.D., MS, Director of the Hypertrophic Cardiomyopathy Center at Oregon Health & Science University
Date: November 17, 2024
Session Title: Cardiomyopathy Mayhem
Session Time: 3:15 PM – 4:20 PM CT
Presentation Time: 4:05 PM – 4:10 PM CT
Location: Zone 2‚ Moderated Digital Poster 5
Title: Changes in EQ-5D-5L with Aficamten in Obstructive Hypertrophic Cardiomyopathy (oHCM): the SEQUOIA-HCM Trial
Presenter: P. Christian Schulze, MD, PhD, Professor of Medicine, Chair, Department of Internal Medicine, Division of Cardiology, Angiology, Pneumology and Intensive Medical Care, University Hospital Jena, Jena, Germany
Date: November 18, 2024
Session Title: Cardiomyopathy Potpourri 2
Session Time: 1:30 PM – 2:30 PM CT
Location: Zone 2
Omecamtiv Mecarbil
Title: Effect of the Cardiac Myosin Activator Omecamtiv Mecarbil on Risk of Ventricular Arrhythmias in Heart Failure with Reduced Ejection Fraction: the GALACTIC-HF Trial
Presenter: Alberto Foà, M.D., Ph.D., Cardiologist, Brigham and Women's Hospital, Harvard Medical School, Boston
Date: November 16, 2024
Session Title: Bulking Up: The Latest in Hypertrophic Cardiomyopathy
Session Time: 2:50 PM – 4:05 PM CT
Presentation Time: 2:50 PM – 2:55 PM CT
Location: Zone 1‚ Moderated Digital Poster 4
Title: Efficacy and Safety of Omecamtiv Mecarbil in Heart Failure with Reduced Ejection Fraction According to Age: the GALACTIC-HF Trial
Presenter: Henri Lu, M.D., Clinical Research Fellow, Heart Failure, Harvard University
Date: November 18, 2024
Session Title: Taking Action to Understand the Ejection Fraction
Session Time: 10:30 AM – 11:30 AM CT
Location: Zone 2
Health Economics and Outcomes Research
Title: Association of Sociodemographic Characteristics on Costs of Care in Patients with Obstructive Hypertrophic Cardiomyopathy
Presenter: Anjali T. Owens, M.D., Medical Director, Center for Inherited Cardiac Disease, Assistant Professor of Medicine, University of Pennsylvania
Date: November 17, 2024
Session Title: Socioeconomic Insights and Innovations in Heart Failure
Session Time: 9:30 AM – 10:55 AM CT
Presentation Time: 9:50 AM – 9:55 AM CT
Location: Zone 2‚ Moderated Digital Poster 5
About Cytokinetics
Cytokinetics is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing muscle biology-directed drug candidates as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact myocardial muscle function and contractility. Following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial evaluating aficamten, a next-in-class cardiac myosin inhibitor, in obstructive hypertrophic cardiomyopathy (HCM), Cytokinetics submitted an NDA for aficamten to the U.S. Food & Drug Administration and is progressing regulatory submissions for aficamten for the treatment of obstructive HCM in Europe. Aficamten is also currently being evaluated in MAPLE-HCM, a Phase 3 clinical trial of aficamten as monotherapy compared to metoprolol as monotherapy in patients with obstructive HCM, ACACIA-HCM, a Phase 3 clinical trial of aficamten in patients with non-obstructive HCM, CEDAR-HCM, a clinical trial of aficamten in a pediatric population with obstructive HCM, and FOREST-HCM, an open-label extension clinical study of aficamten in patients with HCM. Cytokinetics is also developing omecamtiv mecarbil, a cardiac muscle activator, in patients with heart failure. Additionally, Cytokinetics is developing CK-586, a cardiac myosin inhibitor with a mechanism of action distinct from aficamten for the potential treatment of heart failure with preserved ejection fraction (HFpEF).
For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X, LinkedIn, Facebook and YouTube.
Forward-Looking Statements
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics' and its partners' research and development activities of Cytokinetics’ product candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics' business outlined in Cytokinetics' filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and Cytokinetics' actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
CYTOKINETICS® and the CYTOKINETICS and C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.
Contact:
Cytokinetics
Diane Weiser
Senior Vice President, Corporate Affairs
(415) 290-7757
FAQ
What are the main topics of Cytokinetics' presentations at AHA 2024?
When and where will CYTK present at AHA Scientific Sessions 2024?
What are the key findings being presented about Aficamten from the SEQUOIA-HCM trial?
What aspects of Omecamtiv Mecarbil will be discussed from the GALACTIC-HF trial?
